Growth responses following a single intra-muscular hGH plasmid administration compared to daily injections of hGH in dwarf mice

Current Gene Therapy

Volumn 12, Issue 6, 2012, Pages 437-443

  Higuti, Eliza ^a   Cecchi, Cláudia R ^a   Oliveira, Nélio A ^a   Vieira, Daniel P ^a   Jensen, Thomas G ^b   Jorge, Alexander A L ^c   Bartolini, Paolo ^a   Peroni, Cibele N ^a  

^a INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Electroporation; Gene therapy; Human growth hormone; Immunodeficient little mice; Mouse insulin like growth factor I; Naked DNA

Indexed keywords

HUMAN GROWTH HORMONE; PLASMID DNA; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; ELECTROPORATION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GROWTH CURVE; GROWTH HORMONE DEFICIENCY; IN VIVO GENE TRANSFER; MOUSE; NONHUMAN; ORGAN GROWTH; SINGLE DRUG DOSE; WEIGHT GAIN;

ANIMALS; BLOOD GLUCOSE; DWARFISM; ELECTROPORATION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HEART; HUMAN GROWTH HORMONE; HUMANS; INJECTIONS, INTRAMUSCULAR; INSULIN-LIKE GROWTH FACTOR I; KIDNEY; LIVER; MICE; MICE, INBRED BALB C; MICE, SCID; ORGAN SIZE; PLASMIDS; RECOMBINANT PROTEINS; SPLEEN; TIME FACTORS; WEIGHT GAIN;

MUS;

EID: 84870164679     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652312803519797     Document Type: Article

References (43)

1. Fattori E, Cappelletti M, Zampaglione I, et al. Gene electro-transfer of an improved erythropoietin plasmid in mice and non-human primates. J Gene Med 2005; 7: 228-36.
2. Ratanamart J, Shaw JA. Plasmid-mediated muscle-targeted gene therapy for circulating therapeutic protein replacement: a tale of the tortoise and the hare? Curr Gene Ther 2006; 6: 93-110.
3. Prud́homme GJ, Draghia-Akli R, Wang Q. Plasmid-based gene therapy of diabetes mellitus. Gene Ther 2007; 14: 553-64.
4. Bodles-Brakhop AM, Heller R, Draghia-Akli R. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol Ther 2009; 17: 585-92.
5. Gothelf A, Gehl J. Gene electrotransfer to skin; review of existing literature and clinical perspectives. Curr Gene Ther 2010; 10: 287-99.
6. Gothelf A, Hojman P, Gehl J. Therapeutic levels of erythropoietin (EPO) achieved after gene electrotransfer to skin in mice. Gene Ther 2010; 17: 1077-84.
7. Losordo DW, Vale PR, Hendel RC, et al. Phase 1/2 placebocontrolled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002; 105: 2012-18.
8. Melman A, Bar-Chama N, McCullough A, Davies K, Christ G. Plasmid-based gene transfer for treatment of erectile dysfunction and overactive bladder: results of a phase I trial. Isr Med Assoc J 2007; 9: 143-6.
9. Daud AI, DeConti RC, Andrews S, et al. Phase I trial of interleukin- 12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26: 5896-903.
10. Michaluart P, Abdallah KA, Lima FD, et al. Phase I trial of DNAhsp65 immunotherapy for advanced squamous cell carcinoma of the head and neck. Cancer Gene Ther 2008; 15: 676-84.
11. Baumgartner I, Chronos N, Comerota A, et al. Local gene transfer and expression following intramuscular administration of FGF-1 plasmid DNA in patients with critical limb ischemia. Mol Ther 2009; 17: 914-21.
12. Morishita R, Makino H, Aoki M, et al. Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia. Arterioscler Thromb Vasc Biol 2011; 31: 713-20.
13. Gupta R, Tongers J, Losordo DW. Human studies of angiogenic gene therapy. Circ Res 2009; 105: 724-36.
14. Braun S. Muscular gene transfer using nonviral vectors. Curr Gene Ther 2008; 8: 391-405.
15. Murakami T, Sunada Y. Plasmid DNA gene therapy by electroporation: principles and recent advances. Curr Gene Ther 2011; 11: 447-56.
16. Peroni CN, Cecchi CR, Damiani R, et al. High-level secretion of growth hormone by retrovirally transduced primary human keratinocytes: prospects for an animal model of cutaneous gene therapy. Mol Biotechnol 2006; 34: 239-45.
17. Molitch ME, Clemmons DR, Malozowski S, Merrian GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1587-609.
18. Dagnaes-Hansen F, Holst HU, Sondergaard M, et al. Physiological effects of human growth hormone produced after hydrodynamic gene transfer of a plasmid vector containing the human ubiquitin promotor. J Mol Med 2002; 80: 665-70.
19. Sondergaard M, Dagnaes-Hansen F, Flyvbjerg A, Jensen TG. Normalization of growth in hypophysectomized mice using hydrodynamic transfer of the human growth hormone gene. Am J Physiol Endocrinol Metab 2003; 285: E427-E32.
20. Peroni CN, Gout PW, Bartolini P. Animal models for growth hormone gene therapy. Curr Gene Ther 2005; 5: 493-509.
21. Khamaisi M, Sondergaard M, Segev Y, et al. Differential effects on kidney and liver growth of a non-viral hGH-expression vector in hypophysectomized mice. Growth Horm IGF Res 2007; 17: 279-87.
22. Draghia-Akli R, Li XG, Schwartz RJ. Enhanced growth by ectopic expression of growth hormone releasing hormone using an injectable myogenic vector. Nature Biotechnol 1997; 15: 1285-89.
23. Draghia-Akli R, Fiorotto ML, Hill LA, Malone PB, Deaver DR, Schwartz RJ. Myogenic expression of an injectable proteaseresistant growth hormone-releasing hormone augments long-term growth in pigs. Nature Biotechnol 1999; 17: 1179-83.
24. Draghia-Akli R, Hahn KA, King GK, Cumming, KK, Carpenter RH. Effects of plasmid-mediated growth hormone-releasing hormone in severely debilitated dogs with cancer. Mol Ther 2002; 6: 830-6.
25. Draghia-Akli R, Malone PB, Hill LA, Ellis KM, Schwartz RJ, Nordstrom JL. Enhanced animal growth via ligand-regulated GHRH myogenic-injectable vectors. FASEB J 2002; 16: 426-8.
26. Draghia-Akli R, Pope MA, Brown PA, Khan AS. Plasmid-based expression technology using growth hormone releasing hormone: a novel method for physiologically stimulating long-term growth hormone secretion. Comb Chem High Throughput Screen 2006; 9: 181-5.
27. Brown PA, Bodles-Brakhop AM, Pope MA, Draghia-Akli R. Gene therapy by electroporation for the treatment of chronic renal failure in companion animals. BMC Biotechnol 2009; 9: 4.
28. Rocha MG, Marchisotti FG, Osório MG, et al. High prevalence of pituitary magnetic resonance abnormalities and gene mutations in a cohort of Brazilian children with growth hormone deficiency and response to treatment. J Pediatr Endocrinol Metab 2008; 21: 673-80.
29. Khan AS, Draghia-Akli R, Shypailo RJ, Ellis KI, Mersmann H, Fiorotto ML. A comparison of the growth responses following intramuscular GHRH plasmid administration versus daily growth hormone injections in young pigs. Mol Ther 2010; 18: 327-33.
30. Oliveira NAJ, Cecchi CR, Higuti E, et al. Long-term human growth hormone expression and partial phenotypic correction by plasmid-based gene therapy in an animal model of isolated growth hormone deficiency. J Gene Med 2010; 12: 580-5.
31. Eicher EM, Beamer WG. Inherited ateolitic dwarfism in mice. Characteristics of the mutation, little, on chromosome 6. J Hered 1976; 67: 87-91.
32. Jansson JO, Downs TR, Beamer WG, Froham LA. Receptorassociated resistance to growth hormone-releasing factor in dwarf "little" mice. Science 1986; 232: 511-2.
33. Lin SC, Lin CR, Gukovsky I, Lusis AJ, Sawchenko PE, Rosenfeld MG. Molecular basis of the little mouse phenotype and implications for cell type-specific growth. Nature 1993; 364: 208-13.
34. Bellini MH, Bartolini P. In vivo bioassay for the potency determination of human growth hormone in dwarf "little" mice. Endocrinology 1993; 132: 2051-5.
35. Salvatori R. Growth hormone and IGF-I. Rev Endocr Metab Disord 2004; 5: 15-23.
36. Peroni CN, Cecchi CR, Rosauro CW, Nonogaki S, Boccardo E, Bartolini P. Secretion of mouse growth hormone by transduced primary human keratinocytes: prospects for an animal model of cutaneous gene therapy. J Gene Med 2008; 10: 734-43.
37. Bellini MH, Peroni CN, Bartolini P. Increases in weight of growth hormone-deficient and immunodeficient (lit/scid) dwarf mice after grafting of hGH-secreting, primary human keratinocytes. FASEB J 2003; 17: 2322-24.
38. Deitel K, Dantzer D, Ferguson P, et al. Reduced growth of human sarcoma xenografts in hosts homozygous for the lit mutation. J Surg Oncol 2002; 81: 75-9.
39. Schorpp M, Jager R, Schellander K, et al. The human ubiquitin C promoter directs high ubiquitous expression of transgenes in mice. Nucleic Acids Res 1996; 24: 1787-8.
40. Gazdhar A, Bilici M, Jaroslaw P, et al. In vivo electroporation and ubiquitin promoter - a protocol for sustained gene expression in the lung. J Gene Med 2006; 8: 910-8.
41. Ribela MTCP, Murata Y, Morganti L, Toniolo D, Bartolini P. The use of recombinat human growth hormone for radioiodination and standard preparation in radioimmunoassay. J Immunol Methods 1993; 159: 269-74.
42. Oliveira JE, Soares CRJ, Peroni CN, et al. High-yield purification of byosynthetic human growth hormone secreted in Escherichia coli periplasmic space. J Chromatogr A 1999; 852: 441-50.
43. Vijayakumar A, Novosyadlyy R, Wu Y, Yakar S, LeRoith D. Biological effects of growth hormone on carbohydrate and lipid metabolism. Growth Horm IGF Res 2010; 20: 1-7.